1. The effect of morning vs evening exercise training on glycaemic control and serum metabolites in overweight/obese men: a randomised trial
- Author
-
Trine Moholdt, Guro F. Giskeødegård, Julia Debik, Brooke L. Devlin, John A. Hawley, and Evelyn B. Parr
- Subjects
Adult ,Blood Glucose ,Male ,circadian rhythm ,0301 basic medicine ,medicine.medical_specialty ,Evening ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Glycemic Control ,Type 2 diabetes ,Overweight ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Internal Medicine ,medicine ,Humans ,Obesity ,Exercise ,high-intensity interval training ,Uncategorized ,Morning ,Sedentary lifestyle ,business.industry ,Blood Glucose Self-Monitoring ,VO2 max ,Cardiorespiratory fitness ,Middle Aged ,serummetabolomics ,medicine.disease ,high-fat diet ,030104 developmental biology ,Diabetes Mellitus, Type 2 ,blood glucose level ,medicine.symptom ,business ,High-intensity interval training ,Serum metabolomics - Abstract
Aims/hypothesis We determined whether the time of day of exercise training (morning vs evening) would modulate the effects of consumption of a high-fat diet (HFD) on glycaemic control, whole-body health markers and serum metabolomics. Methods In this three-armed parallel-group randomised trial undertaken at a university in Melbourne, Australia, overweight/obese men consumed an HFD (65% of energy from fat) for 11 consecutive days. Participants were recruited via social media and community advertisements. Eligibility criteria for participation were male sex, age 30–45 years, BMI 27.0–35.0 kg/m2 and sedentary lifestyle. The main exclusion criteria were known CVD or type 2 diabetes, taking prescription medications, and shift-work. After 5 days, participants were allocated using a computer random generator to either exercise in the morning (06:30 hours), exercise in the evening (18:30 hours) or no exercise for the subsequent 5 days. Participants and researchers were not blinded to group assignment. Changes in serum metabolites, circulating lipids, cardiorespiratory fitness, BP, and glycaemic control (from continuous glucose monitoring) were compared between groups. Results Twenty-five participants were randomised (morning exercise n = 9; evening exercise n = 8; no exercise n = 8) and 24 participants completed the study and were included in analyses (n = 8 per group). Five days of HFD induced marked perturbations in serum metabolites related to lipid and amino acid metabolism. Exercise training had a smaller impact than the HFD on changes in circulating metabolites, and only exercise undertaken in the evening was able to partly reverse some of the HFD-induced changes in metabolomic profiles. Twenty-four-hour glucose concentrations were lower after 5 days of HFD compared with the participants’ habitual diet (5.3 ± 0.4 vs 5.6 ± 0.4 mmol/l, p = 0.001). There were no significant changes in 24 h glucose concentrations for either exercise group but lower nocturnal glucose levels were observed in participants who trained in the evening, compared with when they consumed the HFD alone (4.9 ± 0.4 vs 5.3 ± 0.3 mmol/l, p = 0.04). Compared with the no-exercise group, peak oxygen uptake improved after both morning (estimated effect 1.3 ml min−1 kg−1 [95% CI 0.5, 2.0], p = 0.003) and evening exercise (estimated effect 1.4 ml min−1 kg−1 [95% CI 0.6, 2.2], p = 0.001). Fasting blood glucose, insulin, cholesterol, triacylglycerol and LDL-cholesterol concentrations decreased only in participants allocated to evening exercise training. There were no unintended or adverse effects. Conclusions/interpretation A short-term HFD in overweight/obese men induced substantial alterations in lipid- and amino acid-related serum metabolites. Improvements in cardiorespiratory fitness were similar regardless of the time of day of exercise training. However, improvements in glycaemic control and partial reversal of HFD-induced changes in metabolic profiles were only observed when participants exercise trained in the evening. Trial registration anzctr.org.au registration no. ACTRN12617000304336. Funding This study was funded by the Novo Nordisk Foundation (NNF14OC0011493). Graphical abstract
- Published
- 2021
- Full Text
- View/download PDF